BOULDER, Colo., May 14 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that data from two Phase I trials of TPI 287, the Company's lead product candidate, will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on Sunday, June 3, 2007. The presentations will take place between 8:00 a.m. and noon.
Clinical investigators will discuss data from two separate Phase I clinical studies of TPI 287 in two poster presentations:
-- "A Phase I study of TPI 287, a next-generation taxane administered weekly in patients with advanced cancer." -- "A Phase I study of TPI 287, a next-generation taxane administered every 21 days in patients with advanced cancer."
Consistent with the disclosure policies of ASCO, Tapestry will summarize the contents of these studies at the time that the posters are presented.
About TPI 287
TPI 287 is a proprietary next-generation taxane being studied for the treatment of multiple cancer indications. In preclinical in vitro tests, TPI 287 has exhibited activity across multiple cell lines, including cell lines that either have developed resistance to taxane therapy or are innately resistant to taxane therapy. In addition, in preclinical in vivo animal xenograft models, TPI 287 has exhibited greater tumor growth inhibition activity compared to standard comparative agents in taxane sensitive and taxane resistant tumor cell lines, including cell lines derived from breast and colon cancers and neuroblastoma tumors.
TPI 287 is currently in clinical studies in the United States. Tapestry plans to initiate multiple Phase II trials for TPI 287 in 2007.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. For more information about Tapestry and its technologies, visit Tapestry's web site at http://www.tapestrypharma.com .
Forward-Looking Statements
Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward-looking statements include the statements that the Company plans to initiate multiple Phase II trials for TPI 287 in 2007. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of Phase II protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 27, 2006 filed with the SEC on March 7, 2007 as well as an amendment thereto on Form 10-K/A filed with the SEC on April 26, 2007. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
Contact: Tapestry Pharmaceuticals, Inc. Gordon Link Senior Vice President, Chief Financial Officer 303-516-8500 glink@tapestrypharma.com Investor: Media: Lilian Stern Dana Conti Stern Investor Relations, Inc. Schwartz Communications 212-362-1200 781-684-0770 lilian@sternir.comtapestry@schwartz-pr.com
Tapestry Pharmaceuticals, Inc.CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer ofTapestry Pharmaceuticals, Inc., +1-303-516-8500, glink@tapestrypharma.com,INVESTORS: Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200,lilian@sternir.com, MEDIA: Dana Conti of Schwartz Communications,+1-781-684-0770, tapestry@schwartz-pr.com, all for TapestryPharmaceuticals, Inc.
Web site: http://www.tapestrypharma.com/
